Skip to Content

Merck KGaA

MRK: XETR (DEU)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€853.00JynrsrXfswjchdt

Merck KGaA Earnings: Weak Life Science and Electronics Segments Cut Into 2023 Outlook

Narrow-moat Merck KGaA delivered weak second-quarter results, and with these trends, management reduced its 2023 outlook. Mild tinkering with our near-term expectations does not materially affect our fair value estimates for the firm (EUR 171/$38), though, and shares continue to trade near fair value, in our opinion.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of MRK so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center